No patient diagnosed with thrombosis in our study had been treated with daratumumab, an anti-CD138 therapy that is now licensed for induction therapy for MM as well as for the relapsed setting by the European Medicines Agency (EMA). This evidence concerns the gene SDC1 and Venous thrombosis.